<DOC>
	<DOCNO>NCT01107444</DOCNO>
	<brief_summary>The purpose study evaluate anti-tumor activity LY2181308 combination docetaxel compare docetaxel alone patient non-small cell lung cancer previously treat first line chemotherapy .</brief_summary>
	<brief_title>Study LY2181308 Combination With Docetaxel Versus Docetaxel Patients With Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Patients nonsmall cell lung cancer locally advance metastatic disease ( Stage IIIB IV entry ) amenable curative therapy progress 1 line chemotherapy Measureable disease define response evaluation criterion solid tumor ( RECIST ) ECOG Performance status 0 1 Must make available exist tumor tissue primary biopsy Patients prior radiation may eligible meet certain criterion Adequate bone marrow reserve organ function Women must negative pregnancy test must comply highly reliable contraceptive method 6 month treatment period . Must breastfeed Men must comply contraceptive regimen 6 month treatment period Currently enrol discontinue clinical trial involve investigational drug/device within last 30 day . Patients may permit enter treatment 30 day wait period special circumstance Pregnant breastfeed Serious concomitant systemic disorder would compromise safety patient patient 's ability complete study Second primary malignancy could affect compliance protocol interpretation study result Known allergy hypersensitivity docetaxel , taxanes , LY2181308 , oligonucleotides , component formulation Patients documented central nervous system brain metastasis time study entry Preexisting neuropathy equivalent common terminology criterion adverse event ( CTCAE ) code great equal 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>